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Abstract
Background: Although several prognostic genomic predictors have been identified from independent studies, it remains
unclear whether these predictors are actually concordant with respect to their predictions for individual patients and which
predictor performs best. We compared five prognostic genomic predictors, the V7RHS, the ColoGuideEx, the Meta163, the
OncoDX, and the MDA114, in terms of predicting disease-free survival in two independent cohorts of patients with
colorectal cancer.
Study Design: Using original classification algorithms, we tested the predictions of five genomic predictors for disease-free
survival in two cohorts of patients with colorectal cancer (n = 229 and n= 168) and evaluated concordance of predictors in
predicting outcomes for individual patients.
Results: We found that only two predictors, OncoDX and MDA114, demonstrated robust performance in identifying
patients with poor prognosis in 2 independent cohorts. These two predictors also had modest but significant concordance
of predicted outcome (r.0.3, P,0.001 in both cohorts).
Conclusions: Further validation of developed genomic predictors is necessary. Despite the limited number of genes shared
by OncoDX and MDA114, individual-patient outcomes predicted by these two predictors were significantly concordant.
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Introduction
Colorectal cancer is the second-leading cause of death from
cancer in the United States, and about 40% of new cases are
diagnosed while the cancer is in the early or localized stage [1].
Because accurate prognosis is essential for selecting the most
effective treatment, considerable effort has been devoted to
establishing a colorectal cancer stratification (or staging) model
for, using clinical information and pathological criteria. Although
clinicopathological staging systems such as the Dukes system and
the American Joint Committee on Cancer (AJCC) system have
been the gold standards as prognostic indicators [2–4], developing
improved prognostic tools is important because the clinical
predictors used currently provide only broad categorization of
risk and fail to identify biological characteristics important for
matching patients with specific therapies.
With the recent advent of microarray technology, risk
assessment for colorectal cancer has been improved by using gene
expression profiling. Researchers at the Ludwig Institute for
Cancer Research and the H. Lee Moffitt Cancer Center identified
a gene expression signature that can predict distant metastasis of
colorectal cancer [5]. A similar genomic prognostic predictor was
developed at The University of Texas MD Anderson Cancer
Center [6]. In a different study, seven genes were identified as a
minimum prognostic gene set, and risk scores for recurrence were
subsequently developed later [7]. Other prognostic genomic
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predictors include Oncotype DX (OncoDX), ColoPrint, ColDx,
and ColoGuideEx [8–11].
Although genes in each prognostic indicator overlap minimally
with those in the other predictors, whether these genetic signatures
identify the same population of patients is unclear [12].
Additionally, the predictive accuracies of the indicators have
never been directly compared in the same cohort of patients with
colorectal cancer. Thus, the question of whether these predictors
are concordant in predicting outcomes for individual patients and
the question of which predictor performs best have not been
resolved previously. In this study, we used various statistical
approaches to determine the concordance of several genomic
predictos in predicting clinical outcomes of individual patients in
two independent cohorts.
Materials and Methods
Prognostic genomic predictors
Using the search terms ‘‘colorectal cancer’’, ‘‘microarray’’, and
‘‘prediction’’, we searched the PubMed database for previously
published studies on prognostic genomic predictors (Figure 1).
This search led us to 36 microarray-based studies on colorectal
cancer. After looking at articles referenced in these studies, we
identified 15 studies that had carried out microarray or reverse
transcriptase-polymerase chain reaction experiments to develop
gene expression-based prognostic predictors [5–11,13–20]. In
those studies, detailed descriptions of the prediction models and
their associated original gene expression data were provided for a
total of six genomic predictors; we selected these six predictors for
further analysis (the remaining nine studies were excluded because
they lacked a full description of the prediction model or primary
data). Of the six selected studies, we excluded the Dukes 50-gene
predictor because the original paper was retracted [18,21].
The 5 prognostic genomic predictors we examined were the (i)
Veridex 7-gene relapse hazard score (V7RHS) developed by Jiang
et al. [7], (ii) metastasis-associated 163-gene expression signature
(Meta163) developed by Jorissen et al. [5], (iii) 7-gene Oncotype
DX recurrence score (OncoDX) developed by Genomic Health
[8], (iv) 114-gene MD Anderson Cancer Center prognostic
predictor (MDA114) developed by Oh et al. [6], and (v) 13-gene
ColoGuideEx prognostic predictor developed by Agesen et al.
[11].
Patients and genomic data
Data with the Gene Expression Omnibus (GEO) accession
number GSE14333 had been generated from fresh-frozen tumor
specimens that had been retrieved from the tissue banks of the
Royal Melbourne Hospital, Western Hospital, and Peter Mac-
Callum Cancer Center in Australia and of the H. Lee Moffitt
Cancer Center in the United States (Australian-US [AUS] cohort,
n = 229) (Table 1) [5]. Of the 229 patients in the AUS cohort, 87
had received standard adjuvant chemotherapy (either single-
treatment 5-fluorouracil/capecitabine or a combination of 5-
fluorouracil and oxaliplatin). The remaining 142 patients had not
received chemotherapy. Disease-free survival (DFS) was defined in
a previous study as the time from surgery to the first confirmed
relapse; data had been censored when a patient died or was alive
without recurrence at last contact [5]. Data with accession
numbers GSE17538 and GSE37892 had been generated from
fresh-frozen tumor specimens of patients at the Vanderbilt
Medical Center and Institut National de la Sante´ et de la
Recherche Me´dicale (INSERM), respectively. The two pooled
data sets were correspond to the VI cohort (n = 168) [19,22].
Gene expression data had been generated by using the
Affymetrix U133 version 2.0 platform. Raw data were download-
ed from the GEO database and normalized using a robust
multiarray averaging method [23].
Figure 1. CONSORT flow diagram for selection of prediction
models.
doi:10.1371/journal.pone.0060778.g001
Table 1. Clinical and pathological characteristics of patients
with colorectal cancer.
Characteristics AUS cohort (N=229) VI cohort (N=168)
Sex
Male 123 90
Female 106 78
Age
Median 67 68
Range 26–92 22–97
Site
Colon 199 168
Rectum 30 0
AJCC Stage
I 44 4
II 94 88
III 91 76
Median Follow-up 47.5 month 50.9 month
Chemotherapy
Yes 87 NA*
No 142 NA
Radiation therapy
Yes 22 NA
No 207 NA
*NA, Not Available
doi:10.1371/journal.pone.0060778.t001
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Stratification of patients according to prognostic
genomic predictors
For patient stratification according to the V7RHS, the log2-
transformed expression level of seven genes (YWHAH, CAPG,
KLF5, EPM2A, LAT, LILRB3, and RCC1 [also known as CHC1]) in
the AUS patients were normalized by subtracting the average
expression values of three housekeeping control genes (ACTB,
HMBS, and RPL13A) to generate DCt values. These 3 genes had
been selected as controls in the original study [7]. The V7RHS for
each patient was derived by summation of the multiplication of the
expression (DCt) values of a gene with its corresponding
coefficients generated from the published regression model
(23.156 for YWHAH, 22.842 for CAPG, +3.002 for KLF5,
22.835 for EPM2A, 23.249 for LAT, 23.215 for LILRB3, and
23.036 for RCC1). Patients with a V7RHS .0 were classified as
high risk, and those with a V7RHS ,0 were classified as low risk
as described previously [7].
The MA163 predictor was developed with gene expression data
from a subset of the AUS cohort, so we followed the same
stratification strategy as that used in a previous study [5]. Briefly,
expression data of 163 gene features in the training set (Dukes
stages A and D) were combined to form a classifier according to
the nearest centroid algorithm. The nearest centroid estimates the
probability that a particular sample belongs to stage A or stage D.
The trained predictor was directly applied to the test set (Dukes
stages B and C) to identify stage A-like and stage D-like patients.
A microarray-based approximation of OncoDX was calculated
by using recurrence score algorithms modified for data from
microarray experiments [8]. First, 12 genes (7 recurrence genes
and 5 reference genes) were identified by using gene symbols.
When multiple probes in the Affymetrix platform represented the
same gene, the gene probes with the highest variance in the gene
expression pattern were selected over others. Second, the
expression levels of the seven recurrence genes (BGN, MYC, FAP,
GADD45B, INHBA, MK167, and MYBL2) were then normalized
by dividing the mean expression levels of the five reference genes
(UBB, ATP5E, PGK1, GPX1, and VDAC2). Third, for the lowest
level of gene expression to equal zero as in the previous study [8],
the normalized expression level of each gene was subtracted by the
minimum expression values across all seven recurrence genes.
Reference normalized expression measurements from microarray
experiments range from 0 to 6.2 on a log2-scale. Fourth, the mean
expression level of each group—cell cycle group (MYBL2, MKI67,
and MYC), stromal group (BGN, FAP, INHBA), and GADD45B
alone—represented group scores as described in the original
algorithm. The unscaled recurrence score (RSu) was calculated
with the use of pre-determined coefficients: 0.12636 stromal
group score–0.31586cell cycle group score +0.34066GADD45B
score. Fifth, the recurrence score was rescaled by multiplying it by
44.16 after adding 0.3 to each RSu according to the original
algorithm, and then subtracting the minimum values of scores
across all patients. Subtraction of the recurrence score (which
made the lowest score equal to 0) was necessary because the lowest
recurrence score was defined as 0 by the original algorithm.
Rescaled recurrence scores ranged from 0 to 88.5. Patients were
then stratified according to the original cut-off for OncoDX by risk
group: low risk, ,30; intermediate risk, 30 to 40; high risk .40.
When patients were stratified into 2 groups, patients with a risk
score of 30 or higher were considered at high risk.
For patient stratification according to the MDA114 predictor,
gene expression data from the original training data set
(GSE17538) were used to train a predictor, and those from
patients in the AUS cohort were used as a test data set as described
previously [6]. Briefly, a compound covariate predictor algorithm
was applied first to the training data set for training of the
predictor and then later to patients in the AUS data set to stratify
patients into two recurrence risk groups, high and low.
With the ColoGuideEx predictor, patients were stratified
according to the number of genes exceeding the 80th and 20th
percentile levels of each gene in the ColoGuideEx signature [11].
High-risk genes (genes whose expression is high in patients with
poor prognosis) are AZGP1, BNIP3, DSC3, ENPP3, EPHA7, KLK6,
SEMA3A, and SESN1. Low-risk genes (genes whose expression is
low in patients with poor prognosis) are CXCL10, CXCL13,
MMP3, PIGR, and TUBA1B. For each patient, the number of
high-risk genes whose expression level was above the 80th
percentile and the number of low-risk genes whose expression
level was below the 20th percentile were counted. The numbers of
genes ranged from 0 to 8. Patients with more than 5 genes were
considered at high risk.
Statistical analysis
Before we applied the prognostic classification algorithms, gene
expression data used as training and test data sets were normalized
by centralizing the gene expression level across the tissues. The
BRB-ArrayTools was used for statistical analysis of gene expres-
sion data [24]. We estimated patient prognoses by using Kaplan-
Meier plots and the log-rank test. We then used multivariate Cox
proportional hazards regression analysis to evaluate independent
prognostic factors associated with survival; we used gene signature,
tumor stage, and pathological characteristics as covariates [25]. A
P value less than 0.05 indicated statistical significance, and all
statistical tests were two-tailed. To assess the strength of the
correlation between outcomes predicted by the different predic-
tors, we applied Cramer’s V statistics and two-way contingency-
table analyses. All statistical analyses were conducted in the R
language environment [26].
Receiver-operating characteristic (ROC) curve analyses were
carried out to estimate the discriminatory power of the prognostic
genomic predictors. Area under the curve (AUC) ranged from 0.5
(for a noninformative predictive marker) to 1 (for a perfect
predictive marker). A bootstrap method (1000 re-sampling) was
used to calculate the 95% confidence interval (CI).
Results
Robustness of prognostic genomic predictors
The number of unique genes in each of the five prognostic
genomic predictors ranged from 7 to 121 (Table S1). Only a few
genes appear on more than one in the five gene lists. MA163 and
MDA114 have the largest numbers of genes, but they share only
seven (Table S2).
By applying the original prediction algorithms and cut-off values
developed in previous studies, we first stratified patients in the
AUS cohort according to the risk level predicted by the five
genomic predictors. Three of the predictors showed significant
association with prognosis; Kaplan-Meier plots and log-rank tests
showed significant differences between the DFS rates of patients
with a high-risk and the DFS rates of those with a low-risk
(Figure 2). Split ratios of patients in the predictors varied from
11.8% and 88.2% (ColoGuideEx) to 51.5% and 48.5% (Meta163)
(Table S3).
To further test the reproducibility and robustness of the
predictions made on the basis of five predictors, we stratified
patients in the VI cohort (n = 168). As with the AUS cohort,
OncoDX and MDA114 showed significant association with
prognosis (Figure 3). Thus, predictions for colorectal cancer
Genomic Predictors of Colorectal Cancer
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patients made on the basis of only two of the five indicators were
reproducible for the two cohorts.
Concordance between predictors
We next evaluated concordance between the predicted
outcomes by comparing the membership of patients predicted
for each risk level. Predicted outcomes varied between the
predictors. For example, of the 86 patients predicted by OncoDX
to have a high or intermediate risk of recurrence, 63 and 60 were
classified by Meta163 and MDA114, respectively, as having poor
prognosis (Table S3 and Figure 1). Likewise, of the 107 patients
predicted by MDA114 to have a high risk of recurrence by
MDA114, only 10 and 22 patients were predicted by ColoGui-
deEx and V7RHS, respectively, to have poor prognosis.
To quantify concordance between the predictors, we applied
Cramer’s V statistics and analyzed two-way contingency-tables for
the AUS cohort (Table 2). The highest correlations were
observed between OncoDX and MDA114 in the AUS cohort
(r = 0.36 by V statistics, P=1.361027 by x2 test). The correlation
between OncoDX and Meta163 was high (r = 0.34 by V statistics,
P=6.861027 by x2 test); correlation between MDA114 and
Meta163 was lower (r = 0.19 by V statistics). When Cramer’s V
statistics were applied to predicted outcomes in the VI cohort, only
the correlation between OncoDX and MDA114 remained
significant (r = 0.39 by V statistics, P=7.561027 by x2 test)
(Table S4). These results suggest that the genomic predictors had
only modest concordance. It is noteworthy that only the robust
predictors OncoDX and MDA114 were significantly concordant
(Table 2 and Table S4).
Figure 2. Kaplan–Meier survival plots of the DFS rates of AUS patients stratified by risk level according to the five genomic
predictors (A to E). DFS data were not available from three patients. P values are based on the log-rank test. Int, intermediate.
doi:10.1371/journal.pone.0060778.g002
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Genomic predictors in relation to clinical variables
Next, we performed univariate Cox analysis with traditional
clinical pathological parameters (gender, age, tumor location,
adjuvant chemotherapy, and AJCC stage) to compare their
prognostic accuracy with that of each predictor (Table S5 and
S6). In agreement with previous analyses, only MDA114 and
Onco DX had significant hazard ratios (HRs) similar to AJCC
stages, for both tested cohorts. We next performed multivariate
Cox analysis by individually analyzing each predictor (Table 3).
V7RHS, ColoGuideEx, and Meta163 were not included in this
analysis due to their lack of association with prognosis in univariate
analyses for both cohorts. For the AUS cohort, MDA114 (HR,
2.26; 95% CI, 1.25–4.1; P=0.007) and OncoDX (HR, 2.38; 95%
CI, 1.32–4.27; P=0.003) were independent variables for predict-
ing DFS.
We also assessed 5-year DFS rates predicted by the five genomic
predictors by calculating area under curves determined by receiver
operating characteristic analysis. Only MDA114 and OncoDX
showed consistent and significant predictive accuracy in both
cohorts (Figure S2). Taken together, our findings suggest that
these two predictors retain prognostic relevance even after the
classic clinicopathological prognostic features are taken into
account.
Genomics predictors in relation to AJCC staging
We next pooled data from the two cohorts to test the degree to
which the predictors are independent from AJCC staging.
Meta163, OncoDX, and ColoGuideEx successfully identified
high-risk patients with AJCC stage II cancer (Figure 4B, 4C,
4E). Likewise, OncoDX and MDA114 showed significantly better
prognostication for patients with stage III disease (Figure 4C and
Figure 3. Kaplan–Meier survival plots of the DFS rates of VI patients stratified by risk level according to the five genomic predictors
(A to E). P values are based on the log-rank test. Int, intermediate.
doi:10.1371/journal.pone.0060778.g003
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4D). These results suggest that some of the genomic predictors
may have stage-specific prognostication characteristics. This needs
to be validated with a larger, prospective cohort.
Genomic predictors in relation to adjuvant
chemotherapy
Since adjuvant chemotherapy data were available for patients in
the AUS cohort, we next sought to determine the association
between outcome predicted by of the genomic predictors and
adjuvant chemotherapy. We carried out a subset analysis for
patients in AJCC stage III (n = 91), a stage for which the benefit of
adjuvant chemotherapy has been well established [27–29].
Patients with stage III disease were subdivided into two risk
groups according to each predictor, and the difference in DFS
between the groups was independently assessed.
Except for MDA114 predictor, most of genomic predictors
failed to show any significant association with adjuvant chemo-
therapy (Figure 5). Subgroup B of MDA114 predictor was only
group benefiting significantly from adjuvant chemotherapy (5-year
DFS rate, 51% with chemotherapy versus 26% without chemo-
therapy; P=0.02 by log-rank test, Figure 5B). In agreement with
the Kaplan-Meier plot and log-rank test, the estimated HR for
relapse with adjuvant chemotherapy in subgroup B was 0.31 (95%
CI, 0.14–0.73; P=0.007), while HR in subgroup A was 0.67 (95%
CI, 0.19–2.34; P=0.5). However, the interaction between
MDA114-based subgrouping and adjuvant chemotherapy did
not reach significance (P=0.36), suggesting that this association
needs to be further tested with a larger prospective cohort.
Discussion
The objective of this study was to conduct an unbiased
comparison of five prognostic genomic predictors and to
determine whether their predictions for individual patients were
concordant. Of the five predictors, only OncoDX and MDA114
identified, in both tested cohorts, patients with poor prognosis.
Although these predictors share only one gene, they predicted
similar outcomes, as evidenced by modest but significant
correlation for pairwise comparisons. The considerable concor-
dance of outcomes predicted by OncoDX and MDA114 suggests
that the gene expression signatures of the two predictors share
similar molecular characteristics that are reflected not in an
individual gene but in a network of genes.
In multivariate Cox proportional-hazards analysis, both On-
coDX and MDA114 were independent variables for predicting
DFS in the two cohorts, suggesting that the use of genomic
predictors may significantly improve current patient prognostica-
tion if the predictors are validated for multiple independent
cohorts. Moreover, the two genomic predictors may overcome the
limitation of current colorectal cancer staging systems, which do
not provide guidance for targeted therapies. Because the gene
expression signatures reflect the biological characteristics of each
risk group, stratification by genomic predictors would offer new
opportunities for rationalized clinical trials to identify subsets of
patients who would receive the maximum benefit of a particular
targeted treatment.
The discriminatory power of ColoGuideEx for identifying high-
risk patients was limited to AJCC stage II in the AUS cohort.
Although our result is in good agreement with those of a previous
study demonstrating that ColoGuideEx was specific to only
patients with stage II disease [11], its stage II-specific prognos-
tification was only marginal in our study, indicating that further
validation of this predictor in a larger, independent cohort is
necessary. Meta163 and OncoDX also showed stage II-specific
prognostication. This finding is consistent with that of a previous
Table 3. Multivariate Cox proportional hazard regression analyses of DFS with clinical variables and genomic predictors.
Oncotype DX MDA114
Variable Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Gender (male or female) 0.99 (0.56–1.7) 0.99 1.03 (0.58–1.8) 0.89
Age (.70 or not) 0.8 (0.43–1.48) 0.48 0.94 (0.5–1.7) 0.85
Location (colon or rectum) 1.23 (0.54–2.8) 0.6 1.3 (0.57–2.9) 0.52
Chemotherapy (yes or no) 0.8 (0.42–1.53) 0.51 0.87 (0.44–1.7) 0.67
Stages (I/II or III) 2.9 (1.67–5.2) 1.961024 4.0 (2.02–8.2) 9.061025
Oncotype DX (high/int or low) 2.38 (1.32–4.27) 0.003
MDA114 (high or low) 2.26 (1.25–4.1) 0.007
doi:10.1371/journal.pone.0060778.t003
Table 2. Concordance of the five genomic predictors in grouping AUS patients by risk level.
Predictors V7RHS Meta163 Oncotype DX MDA114 ColoGuideEx
V7RHS 1 0.08 0.33* 0.4* 0.04
Meta163 0.08 1 0.34 0.19 0.16
Oncotype DX 0.33* 0.34 1 0.36 0.11
MDA114 0.4* 0.19 0.36 1 0.07
ColoGuideEx 0.04 0.16 0.11 0.07 1
Correlation was quantified using Cramer’s V statistics. * Inverse correlation
doi:10.1371/journal.pone.0060778.t002
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study demonstrated the significant accuracy of OncoDX in
predicting recurrence in patients with AJCC stage II disease [30].
Because our current cohorts were not trial cohorts, our analyses
are not intended to be an exhaustive validation of genomic
predictors. For example, all of the patients in the original study for
V7RHS were treated only surgically, whereas patients in our study
received mixed treatments. Thus, a lack of prognostic ability in our
study does not necessarily indicate that one predictor is better or
worse than others.
In conclusion, this study has demonstrated that the indepen-
dently generated genomic predictors MDA114 and OncoDX,
with virtually no overlap between their genes, are concordant in
predicting outcomes for patients with colorectal cancer. The
reason for the lack of overlapping genes among predictors is not
completely known; it may due to differences in technological
platforms, patient cohorts, or mathematical methods of analysis
upon which these assays are based. While genomic predictors have
already provided important insights into the biologic heterogeneity
Figure 4. Kaplan–Meier Plots of DFS rates of all patients grouped by AJCC stage. Patients were stratified by risk level according to the five
predictors (A to E). P values are based on the log-rank test.
doi:10.1371/journal.pone.0060778.g004
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of colorectal cancer, the optimal incorporation of these genomic
tools into clinical practice remains to be accomplished. These
predictors need to be prospectively validated to prove their
superiority in predicting risk of recurrence and benefit beyond the
use of standard clinicopathological prognosis.
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Figure S2 Prognostic accuracy of the five genome
predictors for the AUS (A) and VI (B) cohorts estimated
on the basis of areas under the curve (AUC) from the
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confident internal of AUC.
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Figure 5. Kaplan-Meier plots of the DFS rates of AUS patients with stage III colorectal cancer in AUS cohort. Patients were stratified by
risk level according to the genomic predictors, ColoGuideEx (A), MDA114 (B), Meta163 (C), and OncoDX (D) and grouped by whether they had
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